Chemoendocrine therapy with prolonged estrogen priming in advanced breast cancer: Endocrine pharmacokinetics and toxicity

C. Benz, David R Gandara, B. Miller, T. Drakes, S. Monroe, B. Wilbur, M. DeGregorio

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Recent efforts to improve response rates in advanced breast cancer have used short, alternating courses of antiestrogen therapy followed by estrogen priming to cytokinetically enhance tumor cell sensitivity to antimetabolites. Based on recent in vitro and in vivo studies, we have introduced a chemoendocrine regimen that uses prolonged courses of estrogen priming. The present protocol consists of alternating monthly cycles of tamoxifen (TAM) and estradiol during which sequential (24-hr) methotrexate, 5-fluorouracil, and leucovorin are administered at 2-week intervals. Twenty-five patients with metastatic breast cancer received > 80 endocrine cycles and > 300 courses of chemotherapy by this protocol; two-thirds of these patients had previously failed other endocrine or chemotherapy regimens. Most patients experienced grade 1 or 2 myelosuppression of gastrointestinal symptoms during at least one treatment cycle; however, overall toxicity was considered to be mild and therapy was very well tolerated. Serum levels of estradiol, estrone, TAM and TAM metabolites were measured during all phases of the endocrine cycle in five patients on chronic therapy. Concentrations of TAM and its more abundant metabolite, N-desmethyltamoxifen (N-desTAM), rose twofold during antiestrogen therapy and fell during estrogen priming, with mean levels persisting > 100 ng/ml throughout the priming interval. Mean estradiol (E2) and estrone (E1) levels rose during priming and were sustained fivefold and tenfold above the basal postmenopausal levels measured during antiestrogen treatment. Calculating the serum molar ratios of [TAM + N-desTAM]/[E2 + E1] during each phase of the treatment cycle confirmed that estrogen priming was achieved pharmacologically by this endocrine schedule. Clinical remissions were observed in this small patient sample with seven of 18 patients achieving either complete (28%) or partial (11%) responses, and an additional 39% obtaining disease stabilization. Further clinical study is necessary to evaluate the optimal response rate of this regimen and to determine whether cyclic estrogen priming by this schedule results in enhanced tumor cell proliferation in vivo.

Original languageEnglish (US)
Pages (from-to)283-289
Number of pages7
JournalCancer Treatment Reports
Volume71
Issue number3
StatePublished - 1987

Fingerprint

Estrogens
Pharmacokinetics
Tamoxifen
Breast Neoplasms
Estrogen Receptor Modulators
Estradiol
Estrone
Therapeutics
Appointments and Schedules
Antimetabolites
Drug Therapy
Leucovorin
Serum
Methotrexate
Fluorouracil
Neoplasms
Cell Proliferation
N-desmethyltamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chemoendocrine therapy with prolonged estrogen priming in advanced breast cancer : Endocrine pharmacokinetics and toxicity. / Benz, C.; Gandara, David R; Miller, B.; Drakes, T.; Monroe, S.; Wilbur, B.; DeGregorio, M.

In: Cancer Treatment Reports, Vol. 71, No. 3, 1987, p. 283-289.

Research output: Contribution to journalArticle

Benz, C, Gandara, DR, Miller, B, Drakes, T, Monroe, S, Wilbur, B & DeGregorio, M 1987, 'Chemoendocrine therapy with prolonged estrogen priming in advanced breast cancer: Endocrine pharmacokinetics and toxicity', Cancer Treatment Reports, vol. 71, no. 3, pp. 283-289.
Benz, C. ; Gandara, David R ; Miller, B. ; Drakes, T. ; Monroe, S. ; Wilbur, B. ; DeGregorio, M. / Chemoendocrine therapy with prolonged estrogen priming in advanced breast cancer : Endocrine pharmacokinetics and toxicity. In: Cancer Treatment Reports. 1987 ; Vol. 71, No. 3. pp. 283-289.
@article{29535c2f4cfe4a23bade0c70b2a5eec9,
title = "Chemoendocrine therapy with prolonged estrogen priming in advanced breast cancer: Endocrine pharmacokinetics and toxicity",
abstract = "Recent efforts to improve response rates in advanced breast cancer have used short, alternating courses of antiestrogen therapy followed by estrogen priming to cytokinetically enhance tumor cell sensitivity to antimetabolites. Based on recent in vitro and in vivo studies, we have introduced a chemoendocrine regimen that uses prolonged courses of estrogen priming. The present protocol consists of alternating monthly cycles of tamoxifen (TAM) and estradiol during which sequential (24-hr) methotrexate, 5-fluorouracil, and leucovorin are administered at 2-week intervals. Twenty-five patients with metastatic breast cancer received > 80 endocrine cycles and > 300 courses of chemotherapy by this protocol; two-thirds of these patients had previously failed other endocrine or chemotherapy regimens. Most patients experienced grade 1 or 2 myelosuppression of gastrointestinal symptoms during at least one treatment cycle; however, overall toxicity was considered to be mild and therapy was very well tolerated. Serum levels of estradiol, estrone, TAM and TAM metabolites were measured during all phases of the endocrine cycle in five patients on chronic therapy. Concentrations of TAM and its more abundant metabolite, N-desmethyltamoxifen (N-desTAM), rose twofold during antiestrogen therapy and fell during estrogen priming, with mean levels persisting > 100 ng/ml throughout the priming interval. Mean estradiol (E2) and estrone (E1) levels rose during priming and were sustained fivefold and tenfold above the basal postmenopausal levels measured during antiestrogen treatment. Calculating the serum molar ratios of [TAM + N-desTAM]/[E2 + E1] during each phase of the treatment cycle confirmed that estrogen priming was achieved pharmacologically by this endocrine schedule. Clinical remissions were observed in this small patient sample with seven of 18 patients achieving either complete (28{\%}) or partial (11{\%}) responses, and an additional 39{\%} obtaining disease stabilization. Further clinical study is necessary to evaluate the optimal response rate of this regimen and to determine whether cyclic estrogen priming by this schedule results in enhanced tumor cell proliferation in vivo.",
author = "C. Benz and Gandara, {David R} and B. Miller and T. Drakes and S. Monroe and B. Wilbur and M. DeGregorio",
year = "1987",
language = "English (US)",
volume = "71",
pages = "283--289",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Chemoendocrine therapy with prolonged estrogen priming in advanced breast cancer

T2 - Endocrine pharmacokinetics and toxicity

AU - Benz, C.

AU - Gandara, David R

AU - Miller, B.

AU - Drakes, T.

AU - Monroe, S.

AU - Wilbur, B.

AU - DeGregorio, M.

PY - 1987

Y1 - 1987

N2 - Recent efforts to improve response rates in advanced breast cancer have used short, alternating courses of antiestrogen therapy followed by estrogen priming to cytokinetically enhance tumor cell sensitivity to antimetabolites. Based on recent in vitro and in vivo studies, we have introduced a chemoendocrine regimen that uses prolonged courses of estrogen priming. The present protocol consists of alternating monthly cycles of tamoxifen (TAM) and estradiol during which sequential (24-hr) methotrexate, 5-fluorouracil, and leucovorin are administered at 2-week intervals. Twenty-five patients with metastatic breast cancer received > 80 endocrine cycles and > 300 courses of chemotherapy by this protocol; two-thirds of these patients had previously failed other endocrine or chemotherapy regimens. Most patients experienced grade 1 or 2 myelosuppression of gastrointestinal symptoms during at least one treatment cycle; however, overall toxicity was considered to be mild and therapy was very well tolerated. Serum levels of estradiol, estrone, TAM and TAM metabolites were measured during all phases of the endocrine cycle in five patients on chronic therapy. Concentrations of TAM and its more abundant metabolite, N-desmethyltamoxifen (N-desTAM), rose twofold during antiestrogen therapy and fell during estrogen priming, with mean levels persisting > 100 ng/ml throughout the priming interval. Mean estradiol (E2) and estrone (E1) levels rose during priming and were sustained fivefold and tenfold above the basal postmenopausal levels measured during antiestrogen treatment. Calculating the serum molar ratios of [TAM + N-desTAM]/[E2 + E1] during each phase of the treatment cycle confirmed that estrogen priming was achieved pharmacologically by this endocrine schedule. Clinical remissions were observed in this small patient sample with seven of 18 patients achieving either complete (28%) or partial (11%) responses, and an additional 39% obtaining disease stabilization. Further clinical study is necessary to evaluate the optimal response rate of this regimen and to determine whether cyclic estrogen priming by this schedule results in enhanced tumor cell proliferation in vivo.

AB - Recent efforts to improve response rates in advanced breast cancer have used short, alternating courses of antiestrogen therapy followed by estrogen priming to cytokinetically enhance tumor cell sensitivity to antimetabolites. Based on recent in vitro and in vivo studies, we have introduced a chemoendocrine regimen that uses prolonged courses of estrogen priming. The present protocol consists of alternating monthly cycles of tamoxifen (TAM) and estradiol during which sequential (24-hr) methotrexate, 5-fluorouracil, and leucovorin are administered at 2-week intervals. Twenty-five patients with metastatic breast cancer received > 80 endocrine cycles and > 300 courses of chemotherapy by this protocol; two-thirds of these patients had previously failed other endocrine or chemotherapy regimens. Most patients experienced grade 1 or 2 myelosuppression of gastrointestinal symptoms during at least one treatment cycle; however, overall toxicity was considered to be mild and therapy was very well tolerated. Serum levels of estradiol, estrone, TAM and TAM metabolites were measured during all phases of the endocrine cycle in five patients on chronic therapy. Concentrations of TAM and its more abundant metabolite, N-desmethyltamoxifen (N-desTAM), rose twofold during antiestrogen therapy and fell during estrogen priming, with mean levels persisting > 100 ng/ml throughout the priming interval. Mean estradiol (E2) and estrone (E1) levels rose during priming and were sustained fivefold and tenfold above the basal postmenopausal levels measured during antiestrogen treatment. Calculating the serum molar ratios of [TAM + N-desTAM]/[E2 + E1] during each phase of the treatment cycle confirmed that estrogen priming was achieved pharmacologically by this endocrine schedule. Clinical remissions were observed in this small patient sample with seven of 18 patients achieving either complete (28%) or partial (11%) responses, and an additional 39% obtaining disease stabilization. Further clinical study is necessary to evaluate the optimal response rate of this regimen and to determine whether cyclic estrogen priming by this schedule results in enhanced tumor cell proliferation in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0023112535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023112535&partnerID=8YFLogxK

M3 - Article

C2 - 3493069

AN - SCOPUS:0023112535

VL - 71

SP - 283

EP - 289

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 3

ER -